Trials / Unknown
UnknownNCT04992143
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
The Efficacy and Safety of TACE Combined With Tilelizumab and Sorafenib in Treating BCLC Stage C HCC Patients: a Single-center, Single-arm, Prospective Clinical Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- First Affiliated Hospital of Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
According to the BCLC staging system treatment recommendation, systemic treatment is recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for patients in this stage. Studies have shown that TACE combined with sorafenib therapy has shown effectiveness in the treatment of advanced liver cancer, and PD-1 inhibitors have also shown effectiveness in the treatment of advanced liver cancer. Therefore, in order to improve the survival benefit of BCLC stage C liver cancer patients, this clinical study was designed to evaluate the effectiveness and safety of TACE combined with sorafenib and tislelizumab in the treatment of BCLC stage C liver cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | TACE | TACE first ,and more TACE could be performed when it is necessary. |
| DRUG | Tilelizumab | Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE |
| DRUG | Sorafenib | Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE |
Timeline
- Start date
- 2021-08-20
- Primary completion
- 2023-08-30
- Completion
- 2023-12-30
- First posted
- 2021-08-05
- Last updated
- 2023-02-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04992143. Inclusion in this directory is not an endorsement.